|
|
GLP-1 RA's Role in the Management of Diabetes: Tools For The Primary Care Professional
|
|
Facebook
LinkedIn
E-Mail
|
(4575)
|
Released: 11/01/2024
Expires: 10/31/2025 (subject to change)
- CE for this activity will not be available after this date.
 | This activity includes closed captioning. |
Overview
This program aims to equip primary care professionals with the skills to manage type 2 diabetes more effectively, particularly those who may be hesitant to prescribe glucagon-like peptide-1 receptor agonists (GLP-1 RA). It focuses on applying motivational interviewing techniques to engage patients, developing personalized strategies, and improving medication adherence. The program also emphasizes the use of the latest diabetes management guidelines and therapies, specifically GLP1-RAs, to lower A1C levels and reduce hypoglycemia risk. It encourages understanding their mechanism of action, dosing optimization, administration, glycemic and extra-glycemic effects, safety, tolerability, and place in therapy. Additionally, it guides professionals to develop efficient clinic workflows and communication skills and to identify and overcome barriers contributing to therapeutic inertia and medication reluctance through patient-centered communication and decision-making processes.
Objectives - Apply motivational interview techniques to effectively engage patients in their diabetes management, develop and implement personalized educational strategies tailored to individual patient needs, and utilize various methods to monitor and improve medication adherence among patients with T2D.
- Employ the latest diabetes management guidelines, algorithms, and therapies to increase awareness of the lower risk of hypoglycemia with the use of GLP1-RAs to lower A1C and understand the mechanism of action, dosing optimization, and administration, glycemic and extra-glycemic effects, safety and tolerability information, and place in therapy.
- Develop and implement efficient clinic workflows and communication skills to enhance diabetes care and patient management.
- Identify and overcome barriers contributing to therapeutic inertia and medication reluctance through patient-centered communication and decision-making processes.
Speakers
Debbie Hinnen, APN, BC-ADM, CDCES, FAAN
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP
Inderpreet K. Madahar, MD
Katlyn Diamond, DNP, APRN, ANP-BC, CDES, BC-ADM
Disclosure
This program was planned in accordance with AANP CE Standards and Policies.The speakers have the following disclosures: - Debbie Hinnen:
- Speakers Bureau - Lilly, Novo, Intuity, Sanofi, Theracos Bio;
- Consultant - Novo
- Diana Isaacs:
- Speakers Bureau - Abbott, Dexcom, Medtronic, Insulet, Lilly, Novo Nordisk, Cequr, Sanofi;
- Consultant - Lilly, Sanofi, Medtronic, Lifescan, Sequel, Sanofi
- Inderpreet Madahar:
- Stock ownership - Lilly, Novo Nordisk
- Katlyn Diamond:
- No relevant financial relationships to disclose
All relevant financial relationships have been mitigated.
All Planners involved in this activity have no relevant financial relationships to disclose.
This activity is supported by an educational grant from Novo Nordisk Inc.
Disclaimer
Individuals who have contributed to the CE Center were carefully selected for their knowledge and experience in the subject area under review. This presentation is informational only and may contain opinions of the authors from their personal experience that do not necessarily express the opinions of the American Association of Nurse Practitioners (AANP). The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Clinical practice is a constantly changing process and new information becomes available every day. Neither AANP nor the contributing individuals can warrant that the material will continue to be accurate, nor do they warrant that the material is completely free of errors upon publication. Attendees and participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
CE Credit Instructions- Read this activity description, including objectives and disclosures.
- Complete the educational content:
- Video Presentation:
- Complete the Pretest associated to the activity.
- Click the Play button to watch the activity presentation. Full participation credit for the activity will be received once the entire video has been watched.
- Click on the Additional Resources button to review all additional materials provided (handouts, post-test reviews, any other downloadable resources).
- After completing all content, click on the blue Next Steps button. Complete the post-test and then proceed to the vignette portion of the activity.
- Vignettes:
- Click the Play button on the Vignette activity block to launch the interactive activity. This activity will open in a new window. Complete all parts of the three interactive patient vignettes.
- Click the Next Steps button and complete a short assessment on case-based patient questions.
- Activity Evaluation:
- Click on the Next Steps button from the parent module (top activity block of the activity) and complete the activity evaluation to receive continuing education credit for the full activity.
Additional Information
For questions or more information concerning this online CE activity, please visit the AANP Help Center to find answers to frequently asked questions and request assistance.
1.5 Contact Hour(s) of CE,
0.33 of which may be applied towards Pharmacology
|
|
|
|
Adding Registration, Please wait...
